AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 314119 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 30575484 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (400‐mg tablet once daily)
Number of subjects: 87
Study 30575484 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 87
Study 27244862 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 1000 U/kg intravenously
Number of subjects: 50
Study 27244862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24898834 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 11685
Study 24898834 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Number of subjects: 11685
Study 22402913 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV Biofeedback (BFB) training for 10 consecutive days for 20 min
Number of subjects: 30
Study 22402913 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (motivational video clips for 10 consecutive days for 10 min)
Number of subjects: 30
Study 22402913 — intervention group
Group type: COMPARATOR
Intervention: Control group (No Treatment)
Number of subjects: 30
Study 20197017 — intervention group
Group type: EXPERIMENTAL
Intervention: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac) in Group A (same dose of Tac)
Number of subjects: 92
Study 20197017 — intervention group
Group type: EXPERIMENTAL
Intervention: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac) in Group B (lower dose of Tac)
Number of subjects: 92
Study 20197017 — intervention group
Group type: EXPERIMENTAL
Intervention: Schisandra sphenanthera extract (SchE) co-administered with Tacrolimus (Tac)
Number of subjects: 92
Study 18182621 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 347
Study 18182621 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate
Number of subjects: 347
Study 15942204 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogastrography (EGG) with water load test
Number of subjects: 20
Study 15942204 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogastrography (EGG)
Number of subjects: 20
Study 11829008 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually prescribed coloured overlays
Number of subjects: 33
Study 11829008 — intervention group
Group type: COMPARATOR
Intervention: Control filter
Number of subjects: 33
Study 10980833 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable defibrillator
Number of subjects: 0
Study 7595610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipap support (group II)
Number of subjects: 20
Study 7595610 — intervention group
Group type: COMPARATOR
Intervention: Palliative management (group I)
Number of subjects: 20
Study 2279542 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha interferon (IFN) therapy (1.8 MU/sm/daily for younger patients, 1.0 MU/daily for older patients) followed by splenectomy
Number of subjects: 115
Study 2279542 — intervention group
Group type: COMPARATOR
Intervention: alpha interferon (IFN) therapy (1.8 MU/sm/daily for younger patients, 1.0 MU/daily for older patients) followed by observation
Number of subjects: 115
Study 7002563 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) intravenous infusion at doses up to 4 ng/kg per min
Number of subjects: 6
Study 7002563 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) intravenous infusion at 4 ng/kg per min
Number of subjects: 6
Study 7002563 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) intravenous infusion
Number of subjects: 6
Study 30975057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial-binding dressing (DACC-impregnated surgical dressing)
Number of subjects: 543
Study 27182005 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 5-100 mg single dose
Number of subjects: 100
Study 27182005 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 1-50 mg multiple once-weekly dose
Number of subjects: 100
Study 27182005 — intervention group
Group type: COMPARATOR
Intervention: Omarigliptin (various doses)
Number of subjects: 100
Study 26342062 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal (active) stimulation of 2 mA tDCS to the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study 26342062 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal (active) stimulation of 2 mA tDCS to the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study 26342062 — intervention group
Group type: COMPARATOR
Intervention: Active stimulation of the left primary motor cortex
Number of subjects: 0
Study 26342062 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation of the right DLPFC
Number of subjects: 0
Study 23394494 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol (group T)
Number of subjects: 3
Study 23394494 — intervention group
Group type: COMPARATOR
Intervention: General inhalational anesthesia with sevoflurane (group S)
Number of subjects: 3
Study 23394494 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia (group R)
Number of subjects: 3
Study 21105991 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin (MVAC)
Number of subjects: 295
Study 19671802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (45 mg for patients <100 kg or 90 mg for patients >100 kg, administered subcutaneously; second dose at 4 weeks, then every 8-12 weeks based on response)
Number of subjects: 0
Study 19671802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study 19671802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18038253 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO 160/120 (160 mg Sabal fruit extract WS 1473 and 120 mg Urtica root extract WS 1031 per capsule, 2 x 1 capsule/day)
Number of subjects: 257
Study 18038253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 15506025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec crowns with reduced stump preparations
Number of subjects: 20
Study 15506025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec endo crowns
Number of subjects: 20
Study 10861146 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine treatment group
Number of subjects: 40
Study 10861146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine treatment group
Number of subjects: 40
Study 9092954 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at daily target dosages of 200-1,000 mg/day
Number of subjects: 0
Study 9092954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9092954 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 0
Study 8386650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin combination chemotherapy
Number of subjects: 632
Study 3964314 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis self-management course led by laypersons
Number of subjects: 0
Study 3964314 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis self-management course led by professionals
Number of subjects: 0
Study 3964314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 31566033 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention
Number of subjects: 35
Study 31566033 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 35
Study 30361806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate adherence to statins (proportion of days of follow-up covered 41-80%)
Number of subjects: 6263
Study 30361806 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to statins (proportion of days of follow-up covered >80%)
Number of subjects: 6263
Study 27117144 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation in VLCK diet
Number of subjects: 29
Study 27117144 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric VLCK diet without DHA (control)
Number of subjects: 29
Study 23965645 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg co-administered with simvastatin
Number of subjects: 0
Study 23965645 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4/5 polymorphisms (extensive metabolizers)
Number of subjects: 0
Study 23965645 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal simvastatin dose
Number of subjects: 0
Study 22973094 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric peak torque
Number of subjects: 13
Study 22973094 — intervention group
Group type: EXPERIMENTAL
Intervention: Steep ramp anaerobic test (SRAT)
Number of subjects: 13
Study 22973094 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric peak torque at 90°/sec
Number of subjects: 13
Study 22973094 — intervention group
Group type: EXPERIMENTAL
Intervention: TUG time
Number of subjects: 13
Study 20550071 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated chest percussion therapy (CPT) for 10 minutes
Number of subjects: 30
Study 18600390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interferon-alpha (6 million units daily for 2 weeks, then three times weekly) plus lamivudine (100 mg daily) for 24 weeks followed by lamivudine alone for 28 weeks (n = 30)
Number of subjects: 64
Study 18600390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interferon-alpha plus lamivudine
Number of subjects: 64
Study 18600390 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy (n = 34)
Number of subjects: 64
Study 15811483 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence clinic
Number of subjects: 33
Study 15811483 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 33
Study 12208711 — intervention group
Group type: EXPERIMENTAL
Intervention: LADARVision excimer laser system (LASIK) for spherical hyperopia
Number of subjects: 360
Study 12208711 — intervention group
Group type: EXPERIMENTAL
Intervention: LADARVision excimer laser system (LASIK) for hyperopic astigmatism
Number of subjects: 360
Study 12208711 — intervention group
Group type: EXPERIMENTAL
Intervention: LADARVision excimer laser system (LASIK) for mixed astigmatism
Number of subjects: 360
Study 11040232 — intervention group
Group type: COMPARATOR
Intervention: Obese normotensive subjects
Number of subjects: 59
Study 11040232 — intervention group
Group type: COMPARATOR
Intervention: Lean hypertensive subjects
Number of subjects: 59
Study 11040232 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese hypertensive subjects
Number of subjects: 59
Study 8997656 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothbrush with filaments angled away from the head
Number of subjects: 36
Study 8997656 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush designs (3 types)
Number of subjects: 36
Study 1612948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen of two cycles of cisplatin, bleomycin, vindesine and mitomycin C (first trial, 100 patients)
Number of subjects: 208
Study 1612948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen of three cycles of cisplatin, 5‐fluorouracil by continuous infusion and vindesine (second trial, 108 patients)
Number of subjects: 208
Study 1612948 — intervention group
Group type: EXPERIMENTAL
Intervention: Both chemotherapy regimens
Number of subjects: 208
Study 1612948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 208
Study 6704275 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone 1.2 mg i.v.
Number of subjects: 30
Study 6704275 — intervention group
Group type: COMPARATOR
Intervention: saline 3 ml (placebo)
Number of subjects: 30
Study 31771797 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Monitoring (AM)
Number of subjects: 2640
Study 31219597 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition towards 3.6 years of additional education
Number of subjects: 11348
Study 31219597 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition towards longer education
Number of subjects: 11348
Study 27608536 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith-based intervention including motivational interviewing sessions and church-based group activities
Number of subjects: 71
Study 27608536 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 71
Study 26790207 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion added to FOLFOX chemotherapy regimen
Number of subjects: 60
Study 26790207 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX chemotherapy regimen alone (Control)
Number of subjects: 60
Study 21823199 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioural Therapy (CBT)
Number of subjects: 56
Study 21823199 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-Help (GSH)
Number of subjects: 56
Study 21823199 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Condition
Number of subjects: 56
Study 21506241 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a (135 μg/week for 4 weeks and then 180 μg/week for 44 weeks) plus ribavirin (initial dose of 400 mg/day escalated to 1200 mg/day)
Number of subjects: 115
Study 21506241 — intervention group
Group type: COMPARATOR
Intervention: Observation (treatment initiated upon significant HCV recurrence)
Number of subjects: 115
Study 21506241 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 115
Study 17719752 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 2641
Study 17719752 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 2641
Study 17719752 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 2641
Study 17252706 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic glimepiride tablets (6 mg)
Number of subjects: 24
Study 17252706 — intervention group
Group type: COMPARATOR
Intervention: Innovator glimepiride tablets (6 mg)
Number of subjects: 24
Study 17252706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 14616187 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo-alpha acetylmethadol (LAAM)
Number of subjects: 93
Study 14616187 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 93
Study 11744338 — intervention group
Group type: EXPERIMENTAL
Intervention: ADN plus glutamine 0.15 g x kg(‐1) x d(‐1)
Number of subjects: 23
Study 11744338 — intervention group
Group type: EXPERIMENTAL
Intervention: ADN plus glutamine 0.30 g x kg(‐1) x d(‐1)
Number of subjects: 23
Study 11744338 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional casein‐based enteral formula (ADN)
Number of subjects: 23
Study 11744338 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 23
Study 11744338 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined (after enteral nutrition)
Number of subjects: 23
Study 9419092 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical bipolar cautery tonsillectomy (TEmic)
Number of subjects: 200
Study 9419092 — intervention group
Group type: COMPARATOR
Intervention: Traditional blunt dissection tonsillectomy (TEtrad)
Number of subjects: 200
Study 8121965 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine; specific dosage and duration not mentioned.
Number of subjects: 0
Study 3435906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary SIN-1 (80 micrograms in 4 min)
Number of subjects: 15
Study 3435906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2547030 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC + W (methotrexate, doxorubicin, cyclophosphamide, and lomustine plus warfarin)
Number of subjects: 328
Study 2547030 — intervention group
Group type: COMPARATOR
Intervention: MACC (methotrexate, doxorubicin, cyclophosphamide, and lomustine)
Number of subjects: 328
Study 2547030 — intervention group
Group type: COMPARATOR
Intervention: MEPH/MACC (mitomycin, etoposide, cisplatin, and hexamethylmelamine alternating with MACC)
Number of subjects: 328
Study 2547030 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC + W
Number of subjects: 328
Study 2547030 — intervention group
Group type: COMPARATOR
Intervention: MACC
Number of subjects: 328
Study 2547030 — intervention group
Group type: COMPARATOR
Intervention: MEPH/MACC
Number of subjects: 328
Study 30784097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 to 150 mg BID
Number of subjects: 146
Study 28973174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (0.6 mg/kg; 15% as bolus and 85% as infusion over 1 hour)
Number of subjects: 3297
Study 28973174 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg; 10% as bolus and 90% as infusion over 1 hour)
Number of subjects: 3297
Study 28973174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alteplase
Number of subjects: 3297
Study 28973174 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose alteplase
Number of subjects: 3297
Study 26169991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (15 mg/kg before tourniquet deflation)
Number of subjects: 90
Study 26169991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular TXA (2 g via drain after wound closure)
Number of subjects: 90
Study 26169991 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 90
Study 23948786 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg twice per day)
Number of subjects: 22
Study 23948786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20827510 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens
Number of subjects: 1252
Study 18803739 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative practice model
Number of subjects: 0
Study 18803739 — intervention group
Group type: COMPARATOR
Intervention: Standard care (implied control)
Number of subjects: 0
Study 16894334 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (ESCIT) 10-20 mg/day (flexible dose) or 10 mg/day (fixed dose for the first 4 weeks)
Number of subjects: 40
Study 16894334 — intervention group
Group type: COMPARATOR
Intervention: Estrogen plus progestogen therapy (ethinyl estradiol 5 microg/day plus norethindrone acetate 1 mg/day)
Number of subjects: 40
Study 16894334 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (ESCIT)
Number of subjects: 40
Study 16894334 — intervention group
Group type: COMPARATOR
Intervention: Estrogen plus progestogen therapy (EPT)
Number of subjects: 40
Study 16894334 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 15388905 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental postoperative activity (arm and leg exercises, walking protocol)
Number of subjects: 58
Study 15388905 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative activity
Number of subjects: 58
Study 11305883 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in fundamentalist schools (5-7 years)
Number of subjects: 277
Study 11305883 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in nonfundamentalist schools (5-7 years)
Number of subjects: 277
Study 11305883 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 8-10 years
Number of subjects: 277
Study 11305883 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's natural-history knowledge
Number of subjects: 277
Study 11305883 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's religious interest
Number of subjects: 277
Study 9140675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 16
Study 9140675 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine 10 mg
Number of subjects: 16
Study 9140675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7950558 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in absolute risk reported
Number of subjects: 802
Study 7950558 — intervention group
Group type: EXPERIMENTAL
Intervention: Number needed to treat reported
Number of subjects: 802
Study 7950558 — intervention group
Group type: COMPARATOR
Intervention: Reduction in relative risk reported
Number of subjects: 802
Study 3675696 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1500 mg/d + Ambroxol 90 mg/d (n = 10)
Number of subjects: 23
Study 3675696 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 1500 mg/d (n = 13)
Number of subjects: 23
Study 29235242 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for rheumatoid arthritis with clinical simulation
Number of subjects: 160
Study 29235242 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention for the basic aspects of the diagnosis and treatment of osteoporosis
Number of subjects: 160
Study 27432166 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g) with lifestyle recommendations
Number of subjects: 160
Study 27432166 — intervention group
Group type: COMPARATOR
Intervention: Placebo with lifestyle recommendations
Number of subjects: 160
Study 25022428 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention (IG)
Number of subjects: 177
Study 25022428 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐meeting discussion group (DG)
Number of subjects: 177
Study 25022428 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 177
Study 25022428 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity group (AG)
Number of subjects: 177
Study 22374987 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/3TC
Number of subjects: 56
Study 22374987 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 56
Study 20335626 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phytate maize
Number of subjects: 412
Study 20335626 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg zinc supplement
Number of subjects: 412
Study 20335626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low-phytate maize and zinc supplement
Number of subjects: 412
Study 20335626 — intervention group
Group type: COMPARATOR
Intervention: Control maize
Number of subjects: 412
Study 20335626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412